Lyra therapeutics announces additional data presentations from phase 2 lantern study at the americal rhinologic society annual meeting

Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with lyr-210 (7500Μg) compared to control the three cardinal symptoms composite score shown to correlate with the well-established snot-22 scores at week 24 in the lantern study watertown, mass. , sept. 10, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra) (the company or lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, announced that new lyr-210 data analyses from the phase 2 lantern study will be presented today at the 68th annual meeting of the american rhinologic society (ars) in philadelphia.
LYRA Ratings Summary
LYRA Quant Ranking